Objective: During the latency period of herpes simplex virus type-1 (HSV-1), the virus can occasionally reactivate, travel back to the eye and cause recurrent ocular disease. As this condition arises from the ability of HSV-1 to produce a dormant infection, effective medication to prevent the virus enter a latent state should prevent it. In this study, we applied Echinacea polysaccharide (EP) fraction as prophylactic mediator for latency prevention. Methods: In order to investigate the protective properties of EP, we evaluated its immunostimulatory functions on different immune aspects that play important roles in latency prevention (particularly IFN-γ as one of the main indicators of cellular immunity and latency). Finally, we assessed establishment of latency by detection of thymidine kinase gene in trigeminal ganglia of BALB/c mice. Results: We demonstrated that EP promotes immune response, leading to a reduced latency rate, and it has a promising effect on latency prevention. Conclusion: EP was able to exert an antiviral action on the development of recurrent HSV-1 disease when supplied prior to infection.
© 2009 S. Karger AG, Basel
- Herpes simplex virus type-1
- Echinacea polysaccharide fraction
- Trigeminal ganglion
- Roizman B, Knipe DM, Whitley RJ: Herpes simplex viruses; in Knipe DM, Howley PM (eds): Fields Virology, ed 5. Philadelphia, Lippincott-Raven 2007, vol 2, pp 2501–2602.
- Arduino PG, Porter SR: Herpes simplex virus type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med 2008;37:107–121.
- Richards CM, Case R, Hirst TR, Hill T, Williams NA: Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latency infected mice. J Virol 2003;77:6692–6699.
- Feldman LT, Ellison CC, Voytek L, et al: Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci USA 2002;99:978–983.
- Stanbery LR, Cunningham AL, Mindel A, et al: Prospects for control of herpes simplex virus diseases through immunization. Clin Infect Dis 2000;30:549–599.
- Gordon YJ: The evolution of antiviral therapy for external ocular viral infections over twenty-five years. Cornea 2000;19:673–680.
- Barrett BP, Brown RL, Locken K, et al: Treatment of the common cold with unrefined Echinacea: a randomized, double-blind, placebo controlled trial. Ann Intern Med 2002;137:937–946.
- Mishima S, Saito K, Maruyama H, et al: Antioxidant and immunoenhancing effects of Echinacea purpurea. Biol Pharm Bull 2004;27:1004–1009.
- Currier NL, Miller SC: Echinacea purpurea and melatonin augment natural-killer cells in leukemic mice and prolong life span. J Altern Complement Med 2001;7:241–251.
- Cundell DR, Matrone MA, Ratajczak P: The effect of aerial parts of Echinacea on the circulating white cell levels and selected immune functions of the aging male Sprague-Dawley rat. Int Immunopharmacol 2003;3:1041–1048.
- Goel V, Chang C, Slama JV, et al: Echinacea stimulates macrophage function in the lung and spleen of normal rats. J Nutritional Biochem 2002;13:487–492.
- Schepetkin IA, Quinn MT: Botanical polysaccharides: macrophage immunomodulation and therapeutic potential. Int Immunopharmacol 2006;6:317–333.
- Emmendörffer AC, Wagner H, Lohmann-Matthes ML: Immunologically active polysaccharides from Echinacea purpurea plant and cell cultures; in Wagner H: Immunomodulatory Agents from Plants. Basel, Birkhäuser Verlag, 1999, pp 89–104.
- Steinmüller C, Roesler J, Gröttrup E, Franke G, Wagner H, Lohmann-Matthes ML: Polysaccharides isolated from plant cell cultures of Echinacea purpurea enhance the resistance of immunosuppressed mice against systemic infections with Candida albicans and Listeria monocytogenes. Int J Immunopharmacol 1993;15:605–614.
- Han SB, Park SH, Lee KH, Lee CW, Lee SH, Kim HC, et al: Polysaccharide isolated from the radix of Platycodon grandiflorum selectively activates B cells and macrophages but not T cells. Immunopharmacology 2001;11:1969–1978.
- Ando I, Tsukumo Y, Wakabayashi T, Akashi S, Miyake K, Kataoka T, Nagai K: Safflower polysaccharides activate the transcription factor NF-kappa B via Toll-like receptor 4 and induce cytokine production by macrophages. Int Immunopharmacol 2002;2:1155–1162.
- Ghaemi A, Soleimanjahi H, Gill P, et al: Prophylactic effects of Echinacea purpurea polysaccharide against lethal ocular herpes simplex virus type I. Saudi Med J 2008;29:1203–1205.
- Soleimanjahi H, Roostaee MH, Rasaee MJ, Mahboudi F, Kazemnejad A, Bamdad T, Zandi K: The effect of DNA priming-protein boosting in enhancing the humoral immunity and protecting mice against lethal HSV infections. FEMS Immunol Med Microbiol 2006;46:100–106.
- Jabbar IA, Fernando GJ, Saunders N, Aldovini A, Young R, Malcolm K, Frazer IH: Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000;18:2444–2453.
- Ghaemi A, Soleimanjahi H, Bamdad T, et al: Induction of humoral and cellular immunity against latent HSV-1 infection by DNA immunization in BALB/c mice. Comparative microbiology, immunology and infectious disease. Com Mic Immun Infec Dis 2007;30:197–210.
- Kleinbaum DG, Klein M: Survival analysis; in Gail M, Krickeberg K, Samet JM, Tsiatis A, Wong W (eds): Statistics for Biology and Health, ed 2. New York, Springer, 2005, pp 50–55.
- Corey L: The current trend in genital herpes: progress in prevention. Sex Transm Dis 1994;21:S38–S44.
- Hull C, Spruance S: Situational antiviral drug prophylaxis for HSV type 1 recurrence. Herpes 2007;14:37–40.
- Barrett B: Medicinal properties of Echinacea: a critical review. Phytomedicine 2003;10:66–86.
- Liu T, Khanna KM, Carriere BN, Hendricks RL: Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J Virol 2001;11178–11184.
- Sparks-Thissen RL, Braaten DC, Hildner K: CD4 T cell control of acute and latent murine gamma herpes virus infection requires IFN-γ. Virol 2005;338:201–208.
- Roesler J, Emmendörffer A, Steinmüller C, Luettig B, Wagner H, Lohmann-Matthes ML: Application of purified polysaccharides from cell cultures of plant Echinacea purpurea to test subjects mediates activation of the phagocyte system. Int J Immunopharmacol 1991;13:931–941.
Amir Ghaemi, Hoorieh Soleimanjahi
Department of Virology, School of Medical Sciences, Tarbiat Modares University
P.O. Box 14115-111, Tehran (Iran)
Tel. +98 21 8801 3561, Fax +98 21 8801 3030
E-Mail firstname.lastname@example.org or email@example.com
Received: September 12, 2008
Accepted after revision: February 22, 2009
Published online: April 17, 2009
Number of Print Pages : 6
Number of Figures : 3, Number of Tables : 2, Number of References : 27
Intervirology (International Journal of Basic and Medical Virology)
Vol. 52, No. 1, Year 2009 (Cover Date: May 2009)
Journal Editor: Liebert U.G. (Leipzig)
ISSN: 0300-5526 (Print), eISSN: 1423-0100 (Online)
For additional information: http://www.karger.com/INT
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.